The Latest in Financial & Business News

About a dozen people who have sickle sickle cell disease or relatives with the debilitating blood disorder implored the Food and Drug Administration on Tuesday to approve a revolutionary gene editing treatment — created by CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals — that those who received it in a clinical trial said transformed their lives.

Patients with sickle cell disease urge FDA to greenlight landmark gene-editing treatment

The treatment is administered with a single infusion and was created by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics, which has most of its employees in Mass.

Eli Lilly to pay Beam up to $600 million for DNA-editing tech
The deal gives Cambridge-based Beam a much-needed cash infusion as challenges beset the biotech industry amid the fading pandemic.

Biogen, Eli Lilly present new clinical data in race to field Alzheimer’s treatments
Cambridge-based Biogen is vying with the pharmaceutical giant Eli Lilly for leadership in the emerging multibillion-dollar market for Alzheimer’s therapies.

Late to the game, Mass. drugmakers seek to piggyback on obesity drug boom
Several biotechs in Massachusetts are seeking to elbow their way into the lucrative market, which is dominated by Denmark’s Novo Nordisk and Eli Lilly.

Beam Therapeutics to lay off 100 as it trims costs, narrows research focus
The Cambridge firm is the latest biopharma company in Massachusetts to shed workers in what experts describe as one of the industry’s biggest shakeouts in decades.

Eli Lilly, riding a pharma hot streak, expects to double planned employment in Boston research center
Daniel Skovronsky, Lilly’s chief scientific and medical officer, said the Lilly Institute for Genetic Medicine along Fort Point Channel will ultimately accommodate 500 Lilly scientists and researchers.

FROM OUR PARTNERS

product by Studio/B. What is this?This content was produced by Boston Globe Media's Studio/B in collaboration with the advertiser. The news and editorial departments of the Boston Globe had no role in its production or display.

product by BG BRANDLAB. What is this?This content was produced by Boston Globe Media's Studio/B in collaboration with the advertiser. The news and editorial departments of the Boston Globe had no role in its production or display.

More Life Sciences Headlines

Beam Therapeutics chief executive officer John Evans (left) and president Giuseppe Ciaramella

Beam Therapeutics to lay off 100 as it trims costs, narrows research focus

The Cambridge firm is the latest biopharma company in Massachusetts to shed workers in what experts describe as one of the industry’s biggest shakeouts in decades. 12:34 p.m.

An artist's rendering of the building — currently under construction along Fort Point Channel — where Eli Lilly plans to open its Institute for Genetic Medicine.

Eli Lilly, riding a pharma hot streak, expects to double planned employment in Boston research center

Daniel Skovronsky, Lilly’s chief scientific and medical officer, said the Lilly Institute for Genetic Medicine along Fort Point Channel will ultimately accommodate 500 Lilly scientists and researchers. 5:25 p.m.

Thermo Fisher Scientific is buying Olink Holding, a Swedish company that analyzes proteins, in a $3.1 billion deal.

Waltham-based Thermo Fisher acquires Swedish company for $3.1 billion

Olink specializes in proteomics, the study of the interactions, function, composition, and structures of proteins and their cellular activities. 11:40 a.m.

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy in Chicago. These are four of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act.

Biotech investors push to extend time before pills are subject to price negotiations

Consumer and senior advocates see the lobbying push as another attempt by the pharmaceutical industry to undermine measures to make drugs more affordable for Americans. 7:25 a.m.

European Commissioner for Competition Margrethe Vestager spoke during a media conference at EU headquarters in Brussels on Sept. 6. The European Union on Thursday ordered US biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc.

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The EU already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent. 4:18 p.m.

Andrew Miller, chief operating officer and a founder of Karuna Therapeutics.

Karuna plans to more than double its workforce if schizophrenia drug is approved

Karuna, which began clinical trials of a first-of-its-kind schizophrenia drug called KarXT in 2016, has grown rapidly from about 20 employees in 2020 to more than 300 today. 8:30 a.m.

Robert Janoschek at Nara Park in Acton walked with his dogs. Janoschek is among hundreds of employees who were laid off from Sunovion Pharmaceuticals in Marlborough recently.

‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sector

Thousands of Massachusetts biopharmaceutical workers have been laid off in the past two years in what experts describe as one of the industry’s biggest shakeouts in decades. 5:54 a.m.

Signage outside the Alnylam Pharmaceuticals Inc. office in Cambridge's Kendall Square.

FDA rejects Alnylam’s request to expand approval of one of its drugs to include heart patients

The move follows agency scientists and an advisory panel concluding the drug provided only modest benefits to patients. 10:44 a.m.